Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom.

Breast cancer research : BCR - 8 Mar 2012

King Sharon I, Purdie Colin A, Bray Susan E, Quinlan Philip R, Jordan Lee B, Thompson Alastair M, Meek David W

Abstract excerpt

INTRODUCTION: Polo-like kinase-1 (PLK1) is a crucial driver of cell cycle progression and its down-regulation plays an important checkpoint role in response to DNA damage. Mechanistically, this is mediated by p53 which represses PLK1 expression through chromatin remodelling. Consistent with this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Proteins
Share to Immunohistochemistry
Share to Polo-Like Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins c-mdm2

Share to Survival Rate

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 22405092
DOI: 10.1186/bcr3136
PMCID: PMC3446374

Genes

PLK1
MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22405092-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom.PMID 22405092Read ↗

Comprehensive analysis of PLKs expression and prognosis in breast cancer.Semantic proximity Read ↗

The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?Semantic proximity Read ↗

Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.Semantic proximity Read ↗

Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeuticsSemantic proximity Read ↗

Tumour‐promoting activity of altered WWP1 expression in breast cancer and its utility as a prognostic indicatorSemantic proximity Read ↗

Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cellsSemantic proximity Read ↗

Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapySemantic proximity Read ↗

PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomasSemantic proximity Read ↗

The Role of Polo-like Kinase 1 in Carcinogenesis: Cause or Consequence?Semantic proximity Read ↗

Polo-like kinase 4 (Plk4) potentiates <i>anoikis</i> -resistance of p53KO mammary epithelial cells by inducing a hybrid EMT phenotypeSemantic proximity Read ↗

Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancerSemantic proximity Read ↗

Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.